The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
I have been a bit gutted about the delay because I thought that there would be little interest when we finally received an update (trade volumes have been tiny). Now people have Novacyt back in their sights a positive update should be very warmly received. Due any day now (unless of course there are further delays!).
China remains very pro PCR. Their view on RATS (made in China!) is summed up by their acronym.
Pretty far-fetched I know but could our 10 minute PCR test possibly break through the Chinese market - they still don't seem to have anything close to this.
https://www.dw.com/en/covid-why-are-rapid-tests-banned-in-china/a-60772821
: "In response to the Coronavirus Disease 2019 (COVID-19) public health emergency, FDA's Center for Biologics Evaluation and Research (CBER) has taken steps to prioritize work that advances the nation's response during this national emergency."
I hope we are building something decent stateside.
Kevin C is VP so makes sense. He also shared DT's posts re jobs last week on LI so the US expansion looks like it is happening.
https://www.linkedin.com/feed/update/urn:li:activity:6894054880307240960/
https://www.ft.com/content/c90d17c6-6196-4c8a-88c2-e2cef9a692f2?shareType=nongift
In short, the whole sector has been rocked, especially those with racy valuations but will bounce back.
Big US and European pharma groups have up to $500bn of “dry powder” to spend on acquisitions - 3bn and they can have our little cash cow.
https://www.linkedin.com/posts/robertquirke_digitalhealth-healthpassport-healthcare-activity-6896746475322499072-55uy
Does anyone know why we keep getting tagged in this guys posts on LI?
It looks like Novacyt might be involved in some exciting digital projects but not sure how
Mandy has just confirmed that Coprep will be launched in February. I take that to mean it is ready to go and they have a date lined up that is a bit before the end of Feb (in case there are further delays) but either way, not long now.
All she said on the self-test LFT was that they are awaiting authorisation from CTDA, so that might still be next Feb...
Finally she said there is an updated SP Angel broker note but that it can't be circulated - anyone seen a copy?
Harchris, agree with all you say except there is next to zero percent chance we will 'lose the resolution' tomorrow. Given we have stated on multiple occasions that we have strong grounds we are not going to capitulate in negotiations and pay up so the DHSC would have to sue us. This would take months (years) to resolve. It would be interesting to see what happens if we get an RNS to say we are taking DHSC to court. On the one hand people might panic further but on the other hand people might be encouraged by a real show of strength.
Anyway, good debate by all and more interesting than watching the share price move by 0.0005 euros every few minutes.
This virus is dangerous, and it continues to evolve before our very eyes. WHO is currently tracking four sub-lineages of the Omicron variant of concern, including BA.2.
This virus will continue to evolve, which is why we call on countries to continue testing, surveillance and sequencing. We can’t fight this virus if we don’t know what it’s doing.
I don't think the Gov have the fortitude to take such bold action but one can only hope...
January 2022 – What is the future for COVID testing in the UK?
https://www.linkedin.com/pulse/january-2022-what-future-covid-testing-uk-tony-cooke
I think the details have been shared on here previously. This is my favourite line from the job spec:
With a proven track-record of delivering PCR instrumentation, analysis software and services across a range of applications, we are now expanding and are aiming to further grow to provide the next generation of PCR technology.
Also good to see existing employees promote the roles so vigorously:
https://www.linkedin.com/posts/oranjutanj_careers-activity-6892070475875332096-5DF3
Mina Brett-Pitt from Novacyt Group agreed: "We've met Egyptians, Saudis, Omanis and Nigerian distributors which means new sales, new avenues opening up and exciting new opportunities"
https://www.linkedin.com/posts/jacqueline-balian-1579299_how-to-get-into-the-african-market-gambica-activity-6891707266395893760-aW2d
I've not read it properly but we are named as a major player in US blood grouping reagents market
https://precisionbusinessinsights.com/market-reports/global-blood-grouping-reagents-market/
DRB, couple of points: 1) They said Covid revenue across the market would halve, not Novacyt's share of that - JM sounded pretty bullish that they had plans that would mean that revenue would not half for Novacyt 2) £100m is not entirely from Covid (although I don't think we know the split?).
I personally would be disappointed with future revenue guidance of £50m (even though it still technically ought to mean the sp increases from here).
Hi Chris T
'Having said that, I dont believe they will clear that stock (and the related exceptional cost) off the balance sheet if there's a chance they can claim it back via the dispute resolution.'
Not quite, Novacyt have a duty to mitigate (minimise) their losses so in essence clear the stock at the best possible price and claim back the difference from DHSC
I half wish we were less squeaky clean then we might win some more contracts (at least with UK Gov)! I'm joking btw, the company's bioinformatics report / general whiter than white approach gives me the resolve you need on days (weeks) like these.
Advertised on LI.
2 x NHS managers (this time, southwest and Wales and Scotland and N.East)
2x sales managers in central and Eastern Europe (in addition to the North and South Europe jobs).
As the Liverpool Allez Allez song goes: we've conquered all of Europe...